The FDA has revoked the accelerated approval of adagrasib + cetuximab for KRAS G12C-mutated colorectal cancer.
2026-09-08
Batafsil
Yangiliklar va tadbirlar
Yangiliklar va tadbirlar
Central Asian Cancer Sciences jurnalining e'lonlari, maqolalar uchun chaqiriqlari va tadbirlari.